MediLink Therapeutics Raises $70 Million in Series B Round
Posted on 03/14/2022
MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of a US$ 70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc. The new funding will support clinical development of MediLink’s new generation Antibody-Drug Conjugate (ADC)…
